Thomas J. Oxley (born September 29, 1980) is the chief executive officer of Synchron and neurointerventionist at Mount Sinai Hospital in New York City. Trained as a vascular and interventional neurologist, he established the Vascular Bionics laboratory at the University of Melbourne and is currently co-head of this lab. Oxley is best known for founding Synchron, a company building next-generation brain computer interface solutions that has recently announced the first clinical data on a novel stent electrode (Stentrode) neural interface that is inserted through blood vessels. The company was initiated sometime after his cold-call to DARPA for funding, and has received substantial funding from the U.S. Defense Advanced Research Projects Agency (DARPA) and the Australian government to resear